Department of Center Laboratory, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510700, China.
Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1414 Holcombe Boulevard, Houston, TX, 77030, USA.
J Hematol Oncol. 2019 Sep 14;12(1):99. doi: 10.1186/s13045-019-0788-4.
Cancer immunotherapy has been regarded as the most significant scientific breakthrough of 2013, and antibody therapy is at the core of this breakthrough. Despite significant success achieved in recent years, it is still difficult to target intracellular antigens of tumor cells with traditional antibodies, and novel therapeutic strategies are needed. T cell receptor (TCR)-like antibodies comprise a novel family of antibodies that can recognize peptide/MHC complexes on tumor cell surfaces. TCR-like antibodies can execute specific and significant anti-tumor immunity through several distinct molecular mechanisms, and the success of this type of antibody therapy in melanoma, leukemia, and breast, colon, and prostate tumor models has excited researchers in the immunotherapy field. Here, we summarize the generation strategy, function, and molecular mechanisms of TCR-like antibodies described in publications, focusing on the most significant discoveries.
癌症免疫疗法被认为是 2013 年最重大的科学突破，而抗体疗法是这一突破的核心。尽管近年来取得了重大成功，但用传统抗体靶向肿瘤细胞的细胞内抗原仍然很困难，需要新的治疗策略。T 细胞受体（TCR）样抗体是一类新型抗体，可识别肿瘤细胞表面的肽/MHC 复合物。TCR 样抗体可通过几种不同的分子机制执行特异性和显著的抗肿瘤免疫，这种类型的抗体疗法在黑色素瘤、白血病以及乳腺癌、结肠癌和前列腺肿瘤模型中的成功激发了免疫治疗领域的研究人员的兴趣。在这里，我们总结了已发表文献中描述的 TCR 样抗体的产生策略、功能和分子机制，重点介绍了最重要的发现。
